Showing results (131-140 of 222) with videos related to
Sort By:
Pageof 23
BMC Medical Informatics and Decision Making|October 19, 2019
Utilizing a user-centered approach to develop and assess pharmacogenomic clinical decision support for thiopurine methyltransferaseKhoa A Nguyen, Himalaya Patel, David A Haggstrom, et al.Gastrointestinal Endoscopy|June 4, 2014
A risk index for advanced neoplasia on the second surveillance colonoscopy in patients with previous adenomatous polypsThomas F Imperiale, Ravi Juluri, Eric A Sherer, et al.Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 28, 2026
Effect of Personalized Risk Messages on Patient Intent and Decision Making in Colorectal Cancer Screening: A Randomized Controlled TrialPeter H Schwartz, Thomas F Imperiale, Susan M Perkins, et al.European Journal of Gynaecological Oncology|March 5, 2002
Women with a pelvic mass: indicators of malignancyG C Balbi, R Musone, A Menditto, et al.Annals of Internal Medicine|December 18, 2003
Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancerThomas F Imperiale, David R Wagner, Ching Y Lin, et al.The New England Journal of Medicine|July 20, 2000
Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findingsT F Imperiale, D R Wagner, C Y Lin, et al.Journal of Clinical Gastroenterology|April 7, 2007
A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis CMazen Alsatie, Paul Y Kwo, Joel R Gingerich, et al.Journal of the National Cancer Institute|September 2, 2016
Risk of Advanced Neoplasia Using the National Cancer Institute's Colorectal Cancer Risk Assessment ToolThomas F Imperiale, Menggang Yu, Patrick O Monahan, et al.JAMA Network Open|April 6, 2023
Mortality After Postcolonoscopy Colorectal Cancer in the Veterans Affairs Health Care SystemCharles J Kahi, Laura J Myers, Patrick O Monahan, et al.Prenatal Diagnosis|May 18, 1999
First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy--the combined testP De Biasio, M Siccardi, G Volpe, et al.Pageof 23